(Q47860399)

English

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.

scientific article published on 14 January 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. (English)

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Pierre Vandepapelière

1

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Yves Horsmans

2

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Philippe Moris

3

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Marcelle Van Mechelen

4

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Michel Janssens

5

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Marguerite Koutsoukos

6

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Pascale Van Belle

7

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Frédéric Clement

8

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Emmanuel Hanon

9

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Martine Wettendorff

10

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Nathalie Garçon

11

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Geert Leroux-Roels

12

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

language of work or name

0 references

publication date

14 January 2008

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

26

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

10

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

1375-1386

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Vaccines against intracellular infections requiring cellular immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Progress on new vaccine strategies against chronic viral infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Immunological foundations to the quest for new vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Strategies for designing vaccines eliciting Th1 responses in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Targeting the innate immune response with improved vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Towards the rational design of Th1 adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Vaccine adjuvants revisited

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Smart adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Recent advances in the discovery and delivery of vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Cooperation of Toll-like receptor signals in innate immune defence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Toll-like receptors: critical proteins linking innate and acquired immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Mechanisms of phagocytosis in macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Toll-like receptors control activation of adaptive immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Role of Toll-like receptors in pathogen recognition.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

QS-21: a water-soluble triterpene glycoside adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Therapeutic potential of Toll-like receptor 9 activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

CpG motifs in bacterial DNA and their immune effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

T cell mediated immunity to Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Therapeutic vaccination against chronic viral infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Therapeutic vaccines for chronic infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Progressive differentiation and selection of the fittest in the immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

The immunobiology of the TLR9 subfamily

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Mucosal immunity in the female genital tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Systemic and secretory humoral immunity in the normal human vaginal tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Adjuvants for human vaccines--current status, problems and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Vaccination and autoimmune disease: what is the evidence?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Characterization of a nontoxic monophosphoryl lipid A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

based on heuristic

inferred from DOI database lookup

A study of the cellular and molecular mediators of the adjuvant action of a nontoxic monophosphoryl lipid A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2007.12.038

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47860399&oldid=1540170845"